PMBS Stock UPDATES Puramed Bioscience (PMBS) 0.0001 09/18/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Puramed Bioscience (PMBS) 0.0001 $PMBS

PuraMed BioScience Completes the First Production of MigraPure® Gel
PR Newswire - Wed Aug 13, 11:28AM CDT
PuraMed BioScience®, Inc., (OTCPink MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that the company has completed its first batch of its patented, sublingual MigraPure® gel containing feverfew and ginger with an enhanced flavor.

PuraMed BioScience to add Cannabis-based epilepsy medication to its product line
M2 - Wed Aug 06, 5:53AM CDT
OTC medicinal company PuraMed BioScience (Other OTC MBS) said on Tuesday that it intends to begin testing a new hemp-based epilepsy medication in the fourth quarter of 2014.

PuraMed BioScience Develops a Cannabis-based Epilepsy Medication
PR Newswire - Tue Aug 05, 1:00PM CDT
PuraMed BioScience®, Inc., (OTCPink: PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it plans to begin testing of a new hemp-based epilepsy medication in the fourth quarter of 2014.

PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M
PR Newswire - Wed Jul 30, 12:57PM CDT
PuraMed BioScience®, Inc., (OTCPink MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that the company is rebranding the LipiGesic® M name along with the name's red and yellow logo. The former will be replaced with the trademarked name MigraPure® going forward. The new name, logo, and color palette of PuraMed's homeopathic, natural migraine pain reliever will be reintroduced into selected segments of the retail marketplace.

PuraMed BioScience forms corporate sponsor partnership with Operation Troop Aid for US military
M2 - Wed Jul 23, 7:38AM CDT
Healthcare company PuraMed BioScience (PNK MBS) reported on Tuesday the launch of a corporate sponsor agreement with Operation Troop Aid in aid of the US military.

PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages
PR Newswire - Tue Jul 22, 7:49AM CDT
PuraMed BioScience®, Inc., (OTCBB: PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that the company is a corporate sponsor of Operation Troop Aid.

PuraMed BioScience Announces Product Donation at a Sponsorship Level to Operation Gratitude
PR Newswire - Tue Jul 08, 8:11AM CDT
PuraMed BioScience®, Inc., (OTCBB MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that the company is now a corporate sponsor of Operation Gratitude.

PuraMed BioScience Explores the Development of Hemp and THC-Free Cannabis Formulations to Expand Its Product Line
PRWeb - Mon Mar 24, 6:09AM CDT
PuraMed BioScience(R), Inc., (OTCBB MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, confirmed today that it is seriously exploring the development of cannabinoid and hemp-based formulations to expand its natural and homeopathic product line.

Energy Utilities Focus on Providing Reliable and Safe Service while Meeting Compliance Standards
PR Newswire - Wed Feb 26, 7:00AM CST
To streamline and standardize gas compliance processes and adapt to the demands of the energy service and delivery industry, Ameren Corporation has turned to the mobile workforce management market leader, ClickSoftware Technologies Ltd. (NasdaqGS: CKSW). The implementation of ClickSoftware's scheduling and mobility offering for gas compliance processes will eliminate paper inspection forms and improve data quality, improve flexibility to adapt to rapidly changing regulatory requirements, and provide management with greater visibility into compliance activities.

Merger Approval, Financial Results, Conference Call Schedule, and Stock Price Updates - Research Report on Omnicom, Global Payments, FleetCor, Interpublic, and Fiserv
PR Newswire - Wed Jan 15, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.

PuraMed BioScience Invited to Discuss LipiGesic M on Armed Forces Network
PR Newswire - Thu Aug 29, 11:03AM CDT
PuraMed BioScience®, Inc., (OTCBB MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that it will discuss LipiGesic M on Armed Forces Network.

PuraMed BioScience Sponsors Miles for Migraine Race with LipiGesic M
PR Newswire - Thu Aug 22, 7:00AM CDT
PuraMed BioScience®, Inc., (OTCBB MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it will sponsor the 5th Miles for Migraine Race San Francisco by supplying $5,000 of LipiGesic M for the participants.

PuraMed BioScience Inc signs LipiGesic M distributor agreement with OuterBanks Outdoors
M2 - Thu Aug 15, 10:13AM CDT
Healthcare company PuraMed BioScience Inc (OTC BB MBS) reported on Wednesday the launch of an exclusive distribution agreement to sell LipiGesic M on Amazon.com..

PuraMed BioScience Announces Distributor Agreement with OuterBanks Outdoors
PR Newswire - Wed Aug 14, 1:08PM CDT
PuraMed BioScience®, Inc., (OTCBB MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it has entered into an exclusive distribution agreement with OuterBanks Outdoors to sell LipiGesic® M, its homeopathic formulation of feverfew and ginger for treatment of acute migraine, on Amazon.com.

LipiGesic M is the only recommended first-line therapy for acute migraine that has no evidence of rebound headache
PR Newswire - Mon Aug 05, 2:44PM CDT
PuraMed BioScience®, Inc., (OTCBB MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, confirmed today that its product, LipiGesic® M, a homeopathic formulation of feverfew and ginger that eliminates migraine pain and associated symptoms, is the only recommended first-line therapy for acute migraine in the retail market today that has shown no evidence of rebound or medication-overuse headache.

PuraMed BioScience Inc reports 42.6m outstanding shares in issue
M2 - Wed Jul 03, 4:36AM CDT
Medicinal products company PuraMed BioScience Inc (OTC BB MBS) declared on Tuesday that its current common shares issued and outstanding totalled 42,610,297 as of 30 June 2013.

PuraMed BioScience Announces Common Shares Outstanding of 42.6 Million
PR Newswire - Tue Jul 02, 10:27AM CDT
PuraMed BioScience®, Inc., (OTCBB: PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announces update of current share structure.

PuraMed BioScience® Announces Science Behind LipiGesic® M Migraine Treatment
PR Newswire - Fri Jun 21, 10:05AM CDT
PuraMed BioScience®, Inc., (OTCBB MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced the science behind LipiGesic® M, its homeopathic, over-the-counter migraine medication.

PuraMed BioScience® Announces Interview on Big Biz Show Discussing LipiGesic® M
PR Newswire - Mon Jun 10, 7:00AM CDT
PuraMed BioScience®, Inc., (OTCBB MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced an interview conducted on Big Biz Show with PuraMed BioScience's CEO Russ Mitchell to discuss and inform listeners about PuraMed BioScience's flagship product, LipiGesic® M.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 9

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 12

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 12

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 11

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 8

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 16

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 11

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 12

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 14

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading

Top 5 Most Recently Viewed Articles

Empowering Women Through the Gettysburg Salon Experience

Updated Category News Views 116

Reimagining Women's Spaces Through the Gettysburg Salon The Gettysburg Salon is a vibrant platform where women can express themselves creatively and engage in thought-provoking dialogues. This initiative began with three passionate individuals who envisioned a safe space for women to explore their identities, aspirations, and challenges through art and conversation. In a...

Continue Reading
Transforming Off-Road Adventures: Upfit UTV and OMI Innovation

Updated Category News Views 165

Transforming Off-Road Adventures: Upfit UTV and OMI Innovation Upfit UTV, a subsidiary of Fox Factory known for customizing high-performance vehicles, has joined forces with OMI, a leader in electric powertrain engineering. Together, they are redefining off-road adventures with their groundbreaking Fusion-Drive technology. This innovation not only elevates performance but...

Continue Reading
Investor Alert: AstraZeneca Faces Class Action Lawsuit Under SEC Laws

Updated Category News Views 278

Investor Alert Regarding AstraZeneca Securities Class Action Kahn Swick & Foti, LLC, founded by former Attorney General Charles C. Foti, Jr., is highlighting crucial information for investors in AstraZeneca PLC (NASDAQ: AZN) who may have incurred losses exceeding $100,000. The firm reminds those affected that they need to file lead plaintiff applications for their class...

Continue Reading
Important Class Action for GSK plc Investors: Know Your Rights

Updated Category News Views 208

GSK Faces Class Action Lawsuit: Key Information for Investors Levi & Korsinsky, LLP has announced a class action securities lawsuit involving GSK plc, a well-known pharmaceutical company traded on the NYSE under the ticker GSK. This lawsuit is particularly significant for investors who have been adversely affected during a specified period concerning the securities of...

Continue Reading
Denny’s Fundraiser for No Kid Hungry: Making a Difference

Updated Category News Views 435

Denny’s Annual Fundraiser for No Kid Hungry Returns Denny’s is excited to bring back its annual in-restaurant fundraiser to support No Kid Hungry, a national initiative focused on ending childhood hunger in the United States. This campaign will run for a designated period, allowing Denny's restaurants to make a meaningful difference by ensuring that children have...

Continue Reading